The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Fri, May 20, 2022 | 09:31
Tribune Service
US must lead world vaccine effort
Posted : 2021-10-13 16:46
Updated : 2021-10-13 16:46
Print Preview
Font Size Up
Font Size Down
By Eric Stoner

As someone with a serious genetic respiratory disease, I felt an overwhelming sense of joy and relief to receive the Pfizer-BioNTech COVID-19 vaccine this past spring. I could not have imagined that, several months later, I would be risking arrest by locking arms with others to block the entrance of the pharmaceutical giant's headquarters in New York City.

Dismayed by the growing "vaccine apartheid," as the head of the World Health Organization put it, we called on the company to relinquish its patents and share the technical know-how to manufacture the vaccine. That would allow production to be quickly ramped up throughout the Global South, saving millions of lives.

Like most other wealthy nations, the United States is flush with vaccines ― having already procured more than 1.2 billion doses, or three shots for every person. More than half of the U.S. population is fully vaccinated. But in low-income countries, only 2.3 percent of people have received even one dose.

Meanwhile, the same drug companies that received significant government funding for vaccine development are enjoying historic profits. This is not only morally reprehensible; it's dangerous.

New variants will continue to develop in places that lack access to vaccines, which will eventually cause another deadly wave to batter the United States and indefinitely prolong the pandemic.

If that nightmare scenario unfolds, it will be because we failed to act. The United States is fully able to end this pandemic once and for all, by becoming an "arsenal of vaccines" for the world, as President Joe Biden proclaimed. But so far, his administration has been unwilling to deploy many of the weapons at its disposal.

Facing widespread protests, Biden took a belated but important first step by agreeing to back a temporary waiver for vaccine patents at the World Trade Organization in May. But the administration has not used its clout to break through the continued opposition from the European Union.

That must be a priority, as the access to medicines movement has been urging, but, in the meantime, there is much more that can and should be done.

At least 11 billion doses are needed to inoculate 70 percent of the global population. In September, the White House said it will spend $2.7 billion to scale up the production of critical components for vaccines. But that is a small fraction of the $16 billion allocated for that purpose in the American Rescue Plan last March that has yet to be spent.

Democrats in Congress have gone further with the recent introduction of the NOVID Act, which would invest $34 billion in the global vaccine effort and produce eight billion doses within a year, according to Public Citizen.

If the pharmaceutical industry is unwilling to move quickly, the administration should play hardball. Given that taxpayers almost entirely funded the Moderna vaccine's development through the National Institutes of Health, Biden could exercise a provision in the Bayh-Dole Act that gives the government "march-in" rights to license the patents to manufacturers.

Alternatively, the pandemic could rightly be declared a threat to national security and public health. This would allow the Defense Production Act to be invoked to force vaccine makers to increase production and share their recipes and related technology with other companies abroad.

Waiving intellectual property rights to scale up manufacturing worldwide so that everyone can be vaccinated is not just widely popular. It is a once-in-a-generation opportunity to restore the United States' tattered image around the globe and to save countless lives in the process.

Eric Stoner is a co-founder and editor of Waging Nonviolence and an adjunct professor at St. Joseph's College in Brooklyn, New York. This column was produced for The Progressive magazine and distributed by Tribune News Service.


 
  • People in North Korea trapped in famine and pandemic [PHOTOS]
  • Korea to resume issuing short-term travel visas, e-visas next month
  • Why doctors oppose Nursing Act legislation
  • KBO commissioner proposes holding season openers, regular games in US in meeting with MLB official
  • Luna fiasco escalates into class action by victims
  • Huge fire erupts at S-Oil's Ulsan factory
  • Consumers alarmed by high sodium, saturated fat in meal-kits
  • Black Eagles seek to show ROK Air Force's prowess in England
  • US denial of Biden-Moon meeting triggers speculation
  • Small Seoul temple becomes beacon for religious harmony
  • PSY's first boy group TNX makes much-anticipated debut with EP 'Way Up' PSY's first boy group TNX makes much-anticipated debut with EP 'Way Up'
  • MBC's 'Tomorrow' denies intentional use of BTS members' name, birthdates MBC's 'Tomorrow' denies intentional use of BTS members' name, birthdates
  • [INTERVIEW] Son Suk-ku portrays different villain in 'The Roundup' [INTERVIEW] Son Suk-ku portrays different villain in 'The Roundup'
  • Sequels to hit Korean films await theatrical release this year Sequels to hit Korean films await theatrical release this year
  • Kim Sae-ron apologizes for her alleged DUI incident Kim Sae-ron apologizes for her alleged DUI incident
DARKROOM
  • People in North Korea trapped in famine and pandemic [PHOTOS]

    People in North Korea trapped in famine and pandemic [PHOTOS]

  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

  • End of mask mandates

    End of mask mandates

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group